Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT3FLT4KDRKITPDGFRAPDGFRBRET
The experimentally established mechanism targets of Sunitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 16/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 7/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 3/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.84 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.84 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.84 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.84 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.84 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.84 |
| ▸ | PRKAA2 | P54646 | 12/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.84 |
| ▸ | EGFR | P00533 | 3/20 | 0.84 |
| ▸ | PLK4 | O00444 | 2/20 | 0.84 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.84 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.84 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.84 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.84 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sunitinib SCHEMBL1772213 | 1.00 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL1772212 | 1.00 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL1258610 | 1.00 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL29371243 | 1.00 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL2724453 | 0.93 | KDR (0.89) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL15264678 | 0.92 | KDR (0.93) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL25343935 | 0.92 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL20805212 | 0.92 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL25343938 | 0.92 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL8082 | 0.92 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9733 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731199-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727534-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING BREAST CANCER | Burzynski, Stanislaw R. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| WO-2007142781-A1 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT-TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2007-12-13 | — | — | WO | claimed |
| WO-2007139569-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | claimed |
| WO-2007123892-A2 | RAF INHIBITORS AND THEIR USES | ARQULE INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070231378-A1 | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | GEORGETOWN UNIVERSITY (US) | 2007-10-04 | — | — | US | claimed |
| WO-2007075554-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | claimed |
| WO-2007056117-A1 | ANTINEOPLASTIC COMBINATIONS OF TEMSIROLIMUS AND SUNITINIB MALATE | WYETH (US) | 2007-05-18 | — | — | WO | claimed |
| US-20070105887-A1 | Antineoplastic combinations of temsirolimus and sunitinib malate | WYETH (US) | 2007-05-10 | — | — | US | claimed |
| WO-2007011702-A2 | USE OF EGFR INHIBITORS TO PREVENT OR TREAT OBESITY | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-01-25 | — | — | WO | claimed |
| WO-2006120557-A1 | ANTICANCER COMBINATION THERAPY USING SUNITINIB MALATE | PFIZER INC. (US) | 2006-11-16 | — | — | WO | claimed |